118 related articles for article (PubMed ID: 33433431)
1. Potential role of significant GATA3 mutation in male breast cancer responding to endocrine therapy: A case report.
Xia Y; Liu X; Li W; Zhu Y
Indian J Pathol Microbiol; 2021; 64(1):161-164. PubMed ID: 33433431
[TBL] [Abstract][Full Text] [Related]
2. Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer.
Porter K; Rosenzweig MQ
J Adv Pract Oncol; 2017 Mar; 8(2):164-168. PubMed ID: 29900024
[No Abstract] [Full Text] [Related]
3. Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
Njiaju UO; Truica CI
Clin Breast Cancer; 2010 Feb; 10(1):E3-5. PubMed ID: 20133250
[TBL] [Abstract][Full Text] [Related]
4. [A Case of Male Hereditary Breast Cancer Involving a Sentinel Lymph Node Biopsy].
Tokunou K; Yamamoto T; Yamamoto H; Kamei R; Kitamura Y; Ando S
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2026-2028. PubMed ID: 28133210
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
6. A Case Report of Male Occult Breast Cancer First Manifesting as Axillary Lymph Node Metastasis With Part of Metastatic Mucinous Carcinoma.
He M; Liu H; Jiang Y
Medicine (Baltimore); 2015 Jun; 94(25):e1038. PubMed ID: 26107674
[TBL] [Abstract][Full Text] [Related]
7. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
8. Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report.
Takuwa H; Tsuji W; Shintaku M; Yotsumoto F
BMC Cancer; 2018 Dec; 18(1):1282. PubMed ID: 30577860
[TBL] [Abstract][Full Text] [Related]
9. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer in men.
Buzdar AU
Oncology (Williston Park); 2003 Oct; 17(10):1361-4; discussion 1364, 1369-72. PubMed ID: 14606362
[TBL] [Abstract][Full Text] [Related]
11. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
12. [A Case of Sentinel Lymph Node Biopsy for Male Breast Cancer].
Yamasaki Y; Yamasaki Y; Tsuboi J
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2429-2431. PubMed ID: 28133344
[TBL] [Abstract][Full Text] [Related]
13. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.
Shih J; Bashir B; Gustafson KS; Andrake M; Dunbrack RL; Goldstein LJ; Boumber Y
J Natl Compr Canc Netw; 2015 Aug; 13(8):947-52. PubMed ID: 26285240
[TBL] [Abstract][Full Text] [Related]
14. Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
McLean SR; Shousha S; Francis N; Lim A; Eccles S; Nathan M; Brock CS; Palmieri C
J Cutan Pathol; 2007 Dec; 34(12):934-8. PubMed ID: 18001417
[TBL] [Abstract][Full Text] [Related]
15. [Adenoid cystic carcinoma of the breast:report of 25 cases].
Wei L; Liang X; Li S; Liu J
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):147-50. PubMed ID: 24796466
[TBL] [Abstract][Full Text] [Related]
16. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
17. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
Curigliano G; Criscitiello C
J Clin Oncol; 2017 Aug; 35(23):2600-2603. PubMed ID: 28661760
[TBL] [Abstract][Full Text] [Related]
18. Carcinoma en Cuirasse from Recurrent Breast Cancer seen on FDG-PET/CT.
Win AZ; Aparici CM
J Clin Imaging Sci; 2015; 5():35. PubMed ID: 26180658
[TBL] [Abstract][Full Text] [Related]
19. New approaches in the management of male breast cancer.
Patten DK; Sharifi LK; Fazel M
Clin Breast Cancer; 2013 Oct; 13(5):309-14. PubMed ID: 23845572
[TBL] [Abstract][Full Text] [Related]
20. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.
Hayashi H; Kimura M; Yoshimoto N; Tsuzuki M; Tsunoda N; Fujita T; Yamashita T; Iwata H
Breast Cancer; 2009; 16(2):136-40. PubMed ID: 18548321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
